Displaying 99 (all) recruiting clinical trials.
-
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA
This is a phase 3 clinical trial that compares the effectiveness of two different treatment options in patients who have undergone surgery to remove high-risk ...
-
A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis
A Randomized Double-blind Placebo-controlled study to determine the effect of randomized, once-daily, oral administration of 80 mg resmetirom versus matching placebo on patients with well-compensated ... -
PE-TRACT NYU Enrollment Site
The study is designed to identify the best way to treat pulmonary embolism, specifically when there is a large amount of clot but the patient ... -
A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiranin the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease with METAVIR Stage F2 to F4 Fibrosis
In this study, fazirsiran is being compared with a placebo for patients with alpha-1 antitrypsin deficiency-associated liver disease (AATD LD). A placebo is a liquid ... -
A multicenter international randomized placebo controlled double-blind parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years or older.
OCEANIC-STROKE (study 20604) is a multicenter, international, randomized, placebo controlled, double-blind, parallel group, event driven phase 3 study. The purpose of this study is to ... -
A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (POTEYK-SLE-1)
Researchers hope to learn more about whether deucravacitinib can help in the treatment of SLE and how safe it is to use in people with ... -
I-SPY 2 TRIAL -Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2
The I-SPY 2.2 study is a way to improve how we treat breast cancer. It uses a plan to test new treatments and find ...
-
A Phase 3 Open-Label Randomized Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
This study is being conducted to determine how safe and effective a drug called DZD9008 is compared to standard chemotherapy in patients with locally advanced ... -
OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY
This study is for patients with early-stage triple-negative breast cancer who received a treatment called pembrolizumab (a medicine used to treat melanoma). Some patients will ... -
A Phase 3 Multi-center Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy
The purpose of this research is to study whether an investigational drug, called ampreloxetine, works and how safe it is when taken over several months ...